Search Results | Blood | American Society of Hematology

1-20 of 64

Sort by

Sort Order Select

Journal Articles

Newly revised 2023 MDS response criteria

Rafael Bejar

Blood (2023) 141 (17): 2035–2036.

DOI: https://doi.org/10.1182/blood.2023019821

Published: 2023

Journal Articles

Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia

Blood (2022) 140 (21): 2228–2247.

DOI: https://doi.org/10.1182/blood.2022015853

Published: 2022

Includes: Supplemental data

Journal Articles

A Phase 1a/b Dose Escalation Study of the FLT3/BTK Inhibitor Luxeptinib (CG-806) in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Aaron D Goldberg, Maro Ohanian, Paul B. Koller, Mohamad Cherry, Jessica K. Altman, Benjamin Tomlinson, Namrata Sonia Chandhok, Donna Nguyen Haney, Jia Hu, Ranjeet Kumar Sinha, William G Rice, Rafael Bejar

Blood (2022) 140 (Supplement 1): 6220–6221.

DOI: https://doi.org/10.1182/blood-2022-167759

Published: 2022

Journal Articles

A Phase 1/2 Dose Escalation Study of the Myeloid Kinase Inhibitor HM43239 in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Naval Daver, Kyoo Hyung Lee, Brian A. Jonas, Martha L. Arellano, Chul W. Jung, Sang Kyun Sohn, Sung-Soo Yoon, Jeong-Ok Lee, Jia Hu, Ranjeet Kumar Sinha, William G Rice, Rafael Bejar

Blood (2022) 140 (Supplement 1): 6197–6199.

DOI: https://doi.org/10.1182/blood-2022-167972

Published: 2022

Journal Articles

Incidence, Clinical Associations, and Co-Mutation Patterns of UBA1 Mutations in MDS

Maria Sirenko, Elsa Bernard, David B. Beck, Maria Creignou, Dylan Domenico, Andrea Farina, Juan E Arango, Olivier Kosmider, Robert P. Hasserjian, Martin Jadersten, Ulrich Germing, Guillermo Sanz, Arjan A. van de Loosdrecht, Matilde Y Follo, Felicitas R. Thol, Lurdes Zamora, Ronald Feitosa Pinheiro, Andrea Pellagatti, Harold K. Elias, Detlef Haase, Christina Ganster, Lionel Ades, Magnus Tobiasson, Laura Palomo, Matteo G. Della Porta, Kety Huberman, Pierre Fenaux, Monika Belickova, Michael R. Savona, Virginia M. Klimek, Fabio Pires de Souza Santos, Jacqueline Boultwood, Ioannis Kotsianidis, Valeria Santini, Francesc Solé, Uwe Platzbecker, Michael Heuser, Peter Valent, Carlo Finelli, Maria Teresa Voso, Lee-Yung Shih, Seishi Ogawa, Michaela Fontenay, Joop H. Jansen, Jose Cervera, Benjamin L. Ebert, Rafael Bejar, Peter L Greenberg, Norbert Gattermann, Luca Malcovati, Mario Cazzola, Eva Hellström-Lindberg, Elli Papaemmanuil

Blood (2022) 140 (Supplement 1): 9785–9788.

DOI: https://doi.org/10.1182/blood-2022-162397

Published: 2022

Journal Articles

DNA Methylation Profiles Capture Clinical and Molecular Heterogeneity of MDS and Can be Harnessed for the Development of Robust Biomarkers Predictive of Response to Azacitidine

Qin Yang, Alice Brogi, Elizabeth A. Griffiths, Matilde Y Follo, Carlo Finelli, Jerald P. Radich, Michael J Rauh, Mikkael A. Sekeres, Rafael Bejar, Valeria Santini, Maria Ken E. Figueroa

Blood (2022) 140 (Supplement 1): 9769–9770.

DOI: https://doi.org/10.1182/blood-2022-163704

Published: 2022

Journal Articles

A Phase 1a/b Dose Escalation Study of the BTK/FLT3 Inhibitor Luxeptinib in Patients with Relapsed or Refractory B-Cell Malignancies

Blood (2022) 140 (Supplement 1): 6498–6500.

DOI: https://doi.org/10.1182/blood-2022-163683

Published: 2022

Journal Articles

Subclonal KIT D816V Mutations Are Prevalent in Chronic Myelomonocytic Leukemia and Correlate with Distinct Phenotypic Features

Blood (2022) 140 (Supplement 1): 9824–9827.

DOI: https://doi.org/10.1182/blood-2022-164816

Published: 2022

Journal Articles

Single Cell Deconvolution of Myeloblasts Reveals Depletion of HSCs and Expansion of Inflammatory Granulocyte-Monocyte Progenitors (GMPs) Associated with Adverse Outcomes in Chronic Myelomonocytic Leukemia (CMML)

Abhishek Dhawan, Meghan Ferrall-Fairbanks, Brian Johnson, Hannah Newman, Virginia Volpe, Christopher Letson, Anthony M. Hunter, Maria Balasis, Traci L. Kruer, Jodi Kroeger, Robert Balderas, Rami S. Komrokji, David A. Sallman, Rafael Bejar, Philipp M. Altrock, Eric Padron

Blood (2021) 138 (Supplement 1): 319.

DOI: https://doi.org/10.1182/blood-2021-151348

Published: 2021

Journal Articles

A Phase 1a/b Dose Escalation Study of the MYC Repressor Apto-253 in Patients with Relapsed or Refractory AML or High-Risk MDS

Maro Ohanian, Martha L. Arellano, Moshe Y. Levy, Kristen O'Dwyer, Hani Babiker, Daruka Mahadevan, Hongying Zhang, Nasrin Rastgoo, Yuying Jin, Jotin Marango, Stephen B Howell, William G Rice, Rafael Bejar

Blood (2021) 138 (Supplement 1): 3411.

DOI: https://doi.org/10.1182/blood-2021-150049

Published: 2021

Journal Articles

A Phase 1a/b Dose Escalation Study of the Mutation Agnostic BTK/FLT3 Inhibitor Luxeptinib (CG-806) in Patients with Relapsed or Refractory B-Cell Malignancies

Blood (2021) 138 (Supplement 1): 1355.

DOI: https://doi.org/10.1182/blood-2021-148827

Published: 2021

Journal Articles

A Phase 1a/b Dose Escalation Study of the Mutation Agnostic FLT3/BTK Inhibitor Luxeptinib (CG-806) in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Aaron D Goldberg, Maro Ohanian, Paul Koller, Jessica K. Altman, Mohamad Cherry, Benjamin Tomlinson, Namrata Chandhok, Hongying Zhang, Nasrin Rastgoo, Khalid Benbatoul, Yuying Jin, Genia Su, Jotin Marango, Stephen B Howell, William G Rice, Rafael Bejar

Blood (2021) 138 (Supplement 1): 1272.

DOI: https://doi.org/10.1182/blood-2021-149333

Published: 2021

Journal Articles

Improving Understanding of MDS Using an Animated Patient's Guide to Benefit Patient Health Outcomes

David A. Sallman, MD, Tracey Iraca, Casey L. O'Connell, MD, Rafael Bejar, MD PhD, Sandra Kurtin, ANP

Blood (2020) 136 (Supplement 1): 16–17.

DOI: https://doi.org/10.1182/blood-2020-134647

Published: 2020

Journal Articles

Phenotypic and Proliferative Analysis of T Cell and Monocyte Populations in Patients with Intermediate/High/Very High-Risk MDS Compared to Age-Matched Healthy Donors

Hannah Fields, Valentina Ferrari, BA, Alison Tarke, BS, Randy Guo-Shi Tsai, BS, BA, Timothy Luger, Colin McCarthy, BS, Ruifeng Chen, Xinlian Zhang, Thomas A Lane, MD, Antonella Vitiello, Dr. Pharm., Rafael Bejar, MD PhD, Tiffany N Tanaka, MD

Blood (2020) 136 (Supplement 1): 25–26.

DOI: https://doi.org/10.1182/blood-2020-142038

Published: 2020

Journal Articles

Creating a Variant Database for the American Society of Hematalogy By Consensus Variant Classification of Common Genes Associated with Hematologic Malignancies

Niroshan Nadarajah, Alex Wagner, PhD, Rafael Bejar, MD PhD, Mark Ewalt, MD, Annette S. Kim, MD, Michelle M. Le Beau, PhD, Xiaotu Ma, PhD, Manja Meggendorfer, PhD, Jamile M. Shammo, MD, Gabriella Ryan, Alexa J. Siddon, MD, David P. Steensma, MD, Matthew J. Walter, MD, Ahmet Zehir, PhD, Jinghui Zhang, PhD, Torsten Haferlach, MD

Blood (2020) 136 (Supplement 1): 4–5.

DOI: https://doi.org/10.1182/blood-2020-141204

Published: 2020

Journal Articles

A Phase 1 a/b Dose Escalation Study of the Mutation Agnostic BTK/FLT3 Inhibitor CG-806 in Patients with Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas

Rafael Bejar, MD PhD, Hongying Zhang, MDPhD, Nasrin Rastgoo, PhD, Khalid Benbatoul, BS, Yuying Jin, PhD, Matthew Thayer, BS., Susan Sheng, PhD, Gregory k Chow, BA, MBA, Victor Montalvo-Lugo, Jotin Marango, MD, Stephen B Howell, MD, William G Rice, PhD

Blood (2020) 136 (Supplement 1): 35.

DOI: https://doi.org/10.1182/blood-2020-141495

Published: 2020

Journal Articles

DNA Methylation Analysis before and during Treatment with Azacitidine Plus Pevonedistat or Azacitidine Alone in Patients with MDS, CMML, and AML Previously Untreated with Hypomethylating Agents

Soo Park, MD, Brian M Reilly, BS, Timothy Luger, Dan Zhao, Robert J. Fram, MD, Ajeeta B Dash, PhD, Rafael Bejar, MD PhD

Blood (2020) 136 (Supplement 1): 29–30.

DOI: https://doi.org/10.1182/blood-2020-134484

Published: 2020

Journal Articles

Targeted Sequencing of 7 Genes Can Help Reduce Pathologic Misclassification of MDS

Blood (2020) 136 (Supplement 1): 32–33.

DOI: https://doi.org/10.1182/blood-2020-140317

Published: 2020

Journal Articles

A Phase 1a/b Dose Escalation Study of the MYC Repressor Apto-253 in Patients with Relapsed or Refractory AML or High-Risk MDS

Blood (2020) 136 (Supplement 1): 45–46.

DOI: https://doi.org/10.1182/blood-2020-141409

Published: 2020

Journal Articles

SF3B1 -mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS

Blood (2020) 136 (2): 157–170.

DOI: https://doi.org/10.1182/blood.2020004850

Published: 2020

NARROW

Newly revised 2023 MDS response criteria

Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia

A Phase 1a/b Dose Escalation Study of the FLT3/BTK Inhibitor Luxeptinib (CG-806) in Patients with Relapsed or Refractory Acute Myeloid Leukemia

A Phase 1/2 Dose Escalation Study of the Myeloid Kinase Inhibitor HM43239 in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Incidence, Clinical Associations, and Co-Mutation Patterns of UBA1 Mutations in MDS

DNA Methylation Profiles Capture Clinical and Molecular Heterogeneity of MDS and Can be Harnessed for the Development of Robust Biomarkers Predictive of Response to Azacitidine

A Phase 1a/b Dose Escalation Study of the BTK/FLT3 Inhibitor Luxeptinib in Patients with Relapsed or Refractory B-Cell Malignancies

Subclonal KIT D816V Mutations Are Prevalent in Chronic Myelomonocytic Leukemia and Correlate with Distinct Phenotypic Features

Single Cell Deconvolution of Myeloblasts Reveals Depletion of HSCs and Expansion of Inflammatory Granulocyte-Monocyte Progenitors (GMPs) Associated with Adverse Outcomes in Chronic Myelomonocytic Leukemia (CMML)

A Phase 1a/b Dose Escalation Study of the MYC Repressor Apto-253 in Patients with Relapsed or Refractory AML or High-Risk MDS

A Phase 1a/b Dose Escalation Study of the Mutation Agnostic BTK/FLT3 Inhibitor Luxeptinib (CG-806) in Patients with Relapsed or Refractory B-Cell Malignancies

A Phase 1a/b Dose Escalation Study of the Mutation Agnostic FLT3/BTK Inhibitor Luxeptinib (CG-806) in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Improving Understanding of MDS Using an Animated Patient's Guide to Benefit Patient Health Outcomes

Phenotypic and Proliferative Analysis of T Cell and Monocyte Populations in Patients with Intermediate/High/Very High-Risk MDS Compared to Age-Matched Healthy Donors

Creating a Variant Database for the American Society of Hematalogy By Consensus Variant Classification of Common Genes Associated with Hematologic Malignancies

A Phase 1 a/b Dose Escalation Study of the Mutation Agnostic BTK/FLT3 Inhibitor CG-806 in Patients with Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas

DNA Methylation Analysis before and during Treatment with Azacitidine Plus Pevonedistat or Azacitidine Alone in Patients with MDS, CMML, and AML Previously Untreated with Hypomethylating Agents

Targeted Sequencing of 7 Genes Can Help Reduce Pathologic Misclassification of MDS

A Phase 1a/b Dose Escalation Study of the MYC Repressor Apto-253 in Patients with Relapsed or Refractory AML or High-Risk MDS

SF3B1 -mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only